Interactions between Neuropeptide Y and Noradrenaline Receptor Mechanisms in Sympathetic Vascular Control

  • J. M. Lundberg
  • J. Pernow
  • A. Franco-Cereceda
  • A. Rudehill
Part of the Wenner-Gren Center International Symposium Series book series (WGCISS)


The presence of avian pancreatic polypeptide (APP)-like immunoreactivity (-IR) together with catecholamines in sympathetic cardiovascular nerves and adrenal medulla /1,2/ initiated the search for a novel endogenous peptide. After the isolation of neuropeptide Y (NPY), which has marked structural homology to APP (19 out of 36 amino acids in identical positions) /3/, it was demonstrated that NPY represented the APP-IR initially observed in cardiovascular nerves /4,5/. NPY was found both to exert potent vasoconstrictor activity /4,6/ and to depress the field stimulation-evoked twitch contractions of the vas deferens, suggesting prejunctional inhibition of noradrenaline (NA) release /4,7,8/. Furthermore, electrical stimulation of sympathetic nerves leads to release of not only NA but also of NPY-like immunoreactivity (-LI) /9,10/. Since a considerable part of the vasoconstrictor response to nerve stimulation remained after adrenoceptor blockade /6,9,10/ or NA depletion using reserpine treatment /10/, it has been suggested that NPY could represent a novel transmitter in sympathetic vascular control /see 11/. In this paper we will summarize some recent data which support that NPY fulfils several neurotransmitter criteria and is of importance in peripheral sympathetic vascular control. Furthermore, many drugs used for studies or treatment of hypertension also influence NPY mechanisms in various ways.


Tyrosine Hydroxylase Adrenoceptor Blockade Reserpine Treatment Transmural Nerve Stimulation Perivascular Nerve Fibre 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lundberg JM, Hökfelt T, Änggârd A, Kimmel J, Goldstein M, Markey K. Co-existence of an avian pancreatic polypeptide (APP) immunoreactive substance and catecholamines in some peripheral and central neurons. Acta Physiol Scand 1980: 110: 107–109.CrossRefGoogle Scholar
  2. 2.
    Lundberg JM, Hökfelt T, Änggârd A, Terenius L, Elde R, Markey K, Goldstein M. Organization principles in the peripheral sympathetic nervous system: subdivision by co-existing peptides (somatostatin-, avian pancreatic polypeptide-and vasoactive intestinal polypeptide-like immunoreactive materials). Proc Nat Acad Sci, USA, 1982: 79: 1303–1307.CrossRefGoogle Scholar
  3. 3.
    Tatemoto K. Neuropeptide Y: the complete amino-acid sequence of the brain peptide. Proc Nat Acad Sci, USA, 1982: 79: 5485–5489.CrossRefGoogle Scholar
  4. 4.
    Lundberg JM, Terenius L, Hökfelt T, Martling C-R, Tatemoto K, Mutt V, Polak J, Bloom SR, Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand 1982: 116: 477–480.CrossRefGoogle Scholar
  5. 5.
    Lundberg JM, Terenius L, Hökfelt T, Tatemoto K. Comparative immunohistochemical and biochemical analysis of pancreatic polypeptide-like peptides with special reference to presence of neuropeptide Y in central and peripheral neurons. J Neurosci 1984: 4: 2376–2386.Google Scholar
  6. 6.
    Lundberg JM, Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to alpha-adrenoceptor-resistant sympathetic vasoconstriction. Acta Physiol Scand 1982: 116: 393–402.CrossRefGoogle Scholar
  7. 7.
    Allen JM, Tatemoto K, Polak JM, Hughes J, Bloom SR. Two novel related peptides, neuropeptide Y (NPY) and peptide YY (PYY) inhibit the contraction of the electrically stimulated mouse vas deferens. Neuropeptides 1982: 3: 71–77.CrossRefGoogle Scholar
  8. 8.
    Lundberg JM, Stjärne L. Neuropeptide Y (NPY) depresses the secretion of 3H-noradrenaline and the contractile response evoked by field stimulation in rat vas deferens. Acta Physiol Scand 1984: 120: 477–479.CrossRefGoogle Scholar
  9. 9.
    Lundberg JCI, Änggird A, Theodorsson-Norheim E, Pernow J. Guanethidine-sensitive release of NPY-like immunoreactivity by sympathetic nerve stimulation. Neurosci Lett 1984: 52: 175–180.CrossRefGoogle Scholar
  10. 10.
    Lundberg JH, Rudehill A, Sollevi A, Theodorsson-Norheim E, Hamberger B. Frequency-and reserpinedependent chemical coding of sympathetic transmission: differential release of noradrenaline and neuropeptide Y from pig spleen. Neurosci Lett 1986: 63: 96–100.Google Scholar
  11. 11.
    Lundberg JPI, Hökfelt T. Multiple co-existence of peptides and classical transmitters in peripheral autonomic and sensory neurons–functional and pharmacological implications. In: Hökfelt T, Fuxe K, Pernow B, eds. Progress in Brain Research, Elsevier, Amsterdam, 1986: 68: 241–262.Google Scholar
  12. 12.
    Theodorsson-Norheim E, Hemsén A, Lundberg JM. Radioimmunoassay for neuropeptide Y (NPY): chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand J Lab Invest 1985: 45: 355–365.CrossRefGoogle Scholar
  13. 13.
    Lundberg JM, Martinsson A, Hemsén A, Theodorsson-Norheim E, Svedenhag J, Ekblom E, Hjemdahl P. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun 1985: 133: 30–36.CrossRefGoogle Scholar
  14. 14.
    Lundberg JH, Hökfelt T, Hemsén A, Theodorsson-Norheim E, Pernow J, Hamberger B, Goldstein M. Neuropeptide Y-like immunoreactivity in adrenaline cells of adrenal medulla and in tumors and plasma of phaeochromocytoma patients. Regulatory Peptides 1986: 13: 169–182.CrossRefGoogle Scholar
  15. 15.
    Jonsson G. Chemical lesioning techniques: monoamine neurotoxins. In: Björklund A, Hökfelt T, eds. Methods in chemical neuroanatomy. Elsevier, Amsterdam, 1983:463–507. (Handbook of chemical neuroanatomy; vol. 1).Google Scholar
  16. 16.
    Lundberg Jil, Hemsén A, Larsson O, Rudehill A, Saria A, Fredholm BB. Neuropeptide Y: specific binding sites, second messenger formation foundation and vasoconstrictor activity in pig spleen. N S Arch Pharmacol (submitted).Google Scholar
  17. 17.
    Rudehill A, Lundberg JM, Sollevi A, Hamberger B. Release of neuropeptide Y upon hemorrhagic hypovolemia in relation to vasoconstrictor effects in the pig. Anesthesiology (submitted).Google Scholar
  18. 18.
    Pernow J, Lundberg JM, Kaijser L, Hjemdahl P, Theodorsson-Norheim E, Martinsson A, Pernow B. Plasma neuropeptide Y-like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol 1986: 6: 561–578.CrossRefGoogle Scholar
  19. 19.
    Pernow J, Lundberg JM, Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci (in press).Google Scholar
  20. 20.
    Lundberg JM, Terenius L, Hökfelt T, Goldstein M. High levels of neuropeptide Y (NPY) in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett 1983: 42: 167–172.CrossRefGoogle Scholar
  21. 21.
    Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hâkanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibres. Regul Peptides 1984: 8: 225–235.CrossRefGoogle Scholar
  22. 22.
    Edvinsson L, Emson PC, McCulloch K, Tatemoto K, Uddman R. Neuropeptide Y, cerebrovascular innervation and vasomotor effects in the cat. Neurosci Lett 1983: 43: 79–84.CrossRefGoogle Scholar
  23. 23.
    Edvinsson L, Emson P, McCulloch J, Tatemoto K, Uddman R. Neuropeptide Y: immunocytochemical localization to and effect upon feline pial arteries and veins in vitro and in situ. Acta Physiol Scand 1984: 122: 155–163.CrossRefGoogle Scholar
  24. 24.
    Cannon B, Hökfelt T, Lundberg JM, Terenius L, Goldstein M. Selective distribution of NPY to noradrenergic vascular nerves in brown adipose tissue of the rat. Exp Cell Tissue Res 1986: 164: 546–550.CrossRefGoogle Scholar
  25. 25.
    Fried G. Small noradrenergic storage vesicles isolated from rat vas deferens–biochemical and morphological characterization. Acta Physiol Scand 1980, Suppl. 493: 1–28.Google Scholar
  26. 26.
    Fried G, Lundberg JM, Theodorsson-Norheim E. Subcellular storage and axonal transport of neuropeptide Y (NPY) in relation to catecholamines in the cat. Acta Physiol Scand 1985: 125: 145–154.CrossRefGoogle Scholar
  27. 27.
    Lundberg JM, Saria A, Franco-Cereceda A, Hökfelt T, Terenius L, Goldstein M. Differential effects of reserpine and 6-hydroxydopamine on neuropeptide Y and noradrenaline in peripheral neurons. N S Arch Pharmacol 1985: 328: 331–340.CrossRefGoogle Scholar
  28. 28.
    Lundberg JM, Hemsén A, Fried G, Theodorsson-Norheim E, Lagercrantz H. High plasma levels of neuropeptide Y (NPY)-like immunoreactivity and catecholamines in newborn infants. Acta Physiol Scand 1986: 126: 471–473.CrossRefGoogle Scholar
  29. 29.
    Undén A, Bartfai T. Binding of neuropeptide Y to rat brain membranes. FEBS Letters 1984: 177: 125–128.CrossRefGoogle Scholar
  30. 30.
    Saria A, Theodorsson-Norheim E, Lundberg JM. Evidence for specific neuropeptide Y-binding sites in rat brain synaptosomes. Europ J Pharmacol 1985: 107: 105–107.CrossRefGoogle Scholar
  31. 31.
    Taylor C, Merritt JE. Receptor coupling to polyphosphoinositide turnover: a parallel with the adenylate cyclase system. TIPS 1986: 7: 238–242.Google Scholar
  32. 32.
    Pernow J, Saria A, Lundberg JM. Mechanisms underlying pre-and postjunctional effects of neuropeptide Y in sympathetic vascular control. Acta Physiol Scand 1906: 126: 239–249.CrossRefGoogle Scholar
  33. 33.
    Pernow J, Svendberg T, Lundberg JM. Inhibitory effects of nifedipine on neuropeptide Y and noradrenaline induced contractions of human peripheral blood vessels in vitro. Europ J Pharmacol (submitted).Google Scholar
  34. 34.
    Pernow J, Lundberg JM. Neuropeptide Y contracts human skeletal muscle arteries via a nifedipine-sensitive mechanism independent of extracellular calcium? Acta Physiol Scand (in press).Google Scholar
  35. 35.
    Lundberg JM, Saria A, Anggârd A, Hökfelt T, Terenius L. Neuropeptide Y and noradrenaline interaction in peripheral cardiovascular control. Clin Exp Theory Practice 1984: A6: 1961–1972.CrossRefGoogle Scholar
  36. 36.
    Rioux F, Bachelard H, Martel JC, StPierre S. The vasoconstrictor effects of neuropeptide Y and related peptides on the guinea-pig isolated heart. Peptides 1986: 7: 27–31.CrossRefGoogle Scholar
  37. 37.
    Dahlöf C, Dahlöf P, Lundberg JM. Neurpeptide Y (NPY): enhancement of blood-pressure increase upon alpha-adrenoceptor activation and direct pressor effects in pithed rats. Europ J Pharmacol 1985: 109: 289–292.CrossRefGoogle Scholar
  38. 38.
    Dahlöf C, Tatemoto K, Lundberg JM. Neuropeptide Y (NPY) reduces field stimulation-evoked release of noradrenaline and enhances contractile force in the rat portal vein. N S Arch Pharmacol 1985: 328: 327–330.CrossRefGoogle Scholar
  39. 39.
    Lundberg JM, Saria A, Franco-Cereceda A, Theodorsson-Norheim, E. Treatment with sympatholytic drugs changes tissue content of neuropeptide Y in cardiovascular nerves and adrenal gland. Acta Physiol Scand 1985: 124: 603–611.CrossRefGoogle Scholar
  40. 40.
    Lundberg JM, Al-Saffar A, Saria A, Theodorsson-Norheim E. Reserpine-induced depletion of neuropeptide Y from cardiovascular nerves and adrenal gland due to neurogenic activation. N S Arch Pharmacol 1986: 332: 163–168.CrossRefGoogle Scholar
  41. 41.
    Langer SZ. Pharmacological characterization of alpha-adrenoceptor subtypes. In: Kobinger W, Ahlquist RP, eds. Alpha-and beta-adrenoceptors in the cardiovascular system. Excerpta Medica, 1984: 9–16.Google Scholar
  42. 42.
    Dahlöf C, Dahlöf P, Lundberg JM. Alpha2-adrenoceptor-mediated inhibition of nerve stimulation-evoked release of neuropeptide Y (NPY)-like immunoreactivity in the pithed guinea-pig. Europ J Pharmacol (in press).Google Scholar
  43. 43.
    Nagata A, Franco-Cereceda A, Svensson TH, Lundberg JM. Clonidine treatment elevates the content of neuropeptide Y in cardiac nerves. Acta Physiol Scand 1986: 128: 321–322.CrossRefGoogle Scholar
  44. 44.
    Carlsson A. Drugs which block the storage of 5-hydroxytryptamine and related amines. In: Erspamer, ed. Handbook of experimental pharmacology. Springer Verlag, Berlin-Heidelberg-New York, 1965: 19: 529–592.Google Scholar
  45. 45.
    Lundberg JM, Fried G, Pernow J, Theodorsson-Norheim E, Änggdrd A. NPY–a mediator of reserpine-resistant, non-adrenergic vasoconstriction in cat spleen after preganglionic denervation? Acta Physiol Scand 1986: 126: 151–152.CrossRefGoogle Scholar

Copyright information

© The Wenner-Gren Center 1987

Authors and Affiliations

  • J. M. Lundberg
  • J. Pernow
  • A. Franco-Cereceda
  • A. Rudehill

There are no affiliations available

Personalised recommendations